AbCellera Biologics Inc. ABCL Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares)?
- AbCellera Biologics Inc. (ABCL) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 79.1M in Q1 2026.
- How has AbCellera Biologics Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
- AbCellera Biologics Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 10.0% year-over-year, from 71.9M to 79.1M.
- What is the long-term trend for AbCellera Biologics Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares)?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) has grown at a 18.9% compound annual growth rate (CAGR), from 201.7M to 285.3M.
- What does stock options excluded as their inclusion would be anti-dilutive (in shares) mean?
- The count of stock options or other equity instruments excluded from diluted earnings per share calculations because their exercise price exceeds the current market price. This provides insight into potential future dilution that is currently out-of-the-money.